Wednesday, June 10, 2026
🇺🇸 FDA

pharma · No medical condition. · Generalized Myasthenia Gravis

Anaxis Pharma

Lacuna Pharma Pty Ltd

Anaxis Pharma clinical programs — 223 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Melbourne, AU HQ
2017 Founded
7 Employees
TGA registrant Type
Company details
Status
Public
HQ
Melbourne, AU
Founded
2017
Employees
7
Programs
642
Drugs
673
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Anaxis Pharma projects

223 ClinicalTrials.gov programs sponsored by Anaxis Pharma.

Anaxis Pharma has 223 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

223 programs

Clinical programs

Page 1 of 5

  1. (+)-α-DIHYDROTETRABENAZINE

    Lacuna Pharma Pty Ltd

    Tardive dyskinesia

    phase 2 small molecule active

    1 trial

  2. (+)-α-DIHYDROTETRABENAZINE

    Lacuna Pharma Pty Ltd

    tardive dyskinesia

    phase 2 small molecule active

    1 trial

  3. (+)-α-DIHYDROTETRABENAZINE, ADE513 placebo

    Lacuna Pharma Pty Ltd

    Tardive dyskinesia

    phase 2 small molecule active

    1 trial

  4. -

    Lacuna Pharma Pty Ltd

    Myocardial Infarction, Acute Heart Failure, Left Sided

    phase 2 small molecule active

    1 trial

  5. 1462rot25ct

    Lacuna Pharma Pty Ltd

    Parkinson's disease

    phase 2 small molecule active

    1 trial

  6. 408-C-1402

    Lacuna Pharma Pty Ltd

    Friedreich's ataxia

    phase 2 small molecule active

    1 trial

  7. 747-213

    Lacuna Pharma Pty Ltd

    Primary Biliary Cholangitis (PBC)

    phase 2 small molecule active

    1 trial

  8. ABT-001

    Lacuna Pharma Pty Ltd

    Mucopolysaccharidosis type IIIA

    phase 2 small molecule active

    1 trial

  9. ABT-C11-2020

    Lacuna Pharma Pty Ltd

    Metastatic pancreatic ductal adenocarcinoma

    phase 2 small molecule active

    1 trial

  10. AC102-201

    Lacuna Pharma Pty Ltd

    Idiopathic Sudden Sensorineural Hearing Loss

    phase 2 small molecule active

    1 trial

  11. ACE-CL-001

    Lacuna Pharma Pty Ltd

    Richter's Syndrome, Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  12. ACE-LY-003

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory marginal zone lymphoma

    phase 2 small molecule active

    1 trial

  13. ACE-LY-004

    Lacuna Pharma Pty Ltd

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  14. ACE-WM-001

    Lacuna Pharma Pty Ltd

    Waldenström Macroglobulinemia

    phase 2 small molecule active

    1 trial

  15. ACP-103-070

    Lacuna Pharma Pty Ltd

    Irritability associated with autistic disorder in children and adolescents with ASD

    phase 2 small molecule active

    1 trial

  16. ACT-1004-1239 matching placebo

    Lacuna Pharma Pty Ltd

    Progressive multiple sclerosis (MS)

    phase 2 small molecule active

    1 trial

  17. ADX-038

    Lacuna Pharma Pty Ltd

    Complement-Mediated Kidney Disease

    phase 2 small molecule active

    1 trial

  18. ADX-038-202

    Lacuna Pharma Pty Ltd

    Geographic atrophy secondary to age-related macular degeneration

    phase 2 small molecule active

    1 trial

  19. AG946-C-003

    Lacuna Pharma Pty Ltd

    Sickle Cell Disease

    phase 2 small molecule active

    1 trial

  20. AH0003

    Lacuna Pharma Pty Ltd

    Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  21. AL8326

    Lacuna Pharma Pty Ltd

    Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage., Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage.

    phase 2 small molecule active

    1 trial

  22. AL8326

    Lacuna Pharma Pty Ltd

    - Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage. - Non Small Cell Lung Cancer (NSCLC) patients who need ≥2nd line treatment with brain metastasis which is controlled with no active hemorrhage. - Renal Cell Carcinoma (RCC) patients who need ≥2nd line treatment., - Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage. - Non Small Cell Lung Cancer (NSCLC) patients who need ≥2nd line treatment with brain metastasis which is controlled with no active hemorrhage. - Renal Cell Carcinoma (RCC) patients who need ≥2nd line treatment.

    phase 2 small molecule active

    1 trial

  23. ALDARA 5% cream, Keramod® gel

    Lacuna Pharma Pty Ltd

    Actinic keratosis

    phase 2 small molecule active

    1 trial

  24. AMY106EU

    Lacuna Pharma Pty Ltd

    Endometriosis

    phase 2 small molecule active

    1 trial

  25. ANN-008

    Lacuna Pharma Pty Ltd

    Diabetic Retinopathy, Retinal Vein Occlusion

    phase 2 other active

    1 trial

  26. AP-recAP-CSA-RD-0201

    Lacuna Pharma Pty Ltd

    Risk for renal damage following open heart surgery

    phase 2 small molecule active

    1 trial

  27. AP01-007

    Lacuna Pharma Pty Ltd

    Progressive Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial

  28. AP01-201

    Lacuna Pharma Pty Ltd

    Acute Heart Failure

    phase 2 small molecule active

    1 trial

  29. AP02-003

    Lacuna Pharma Pty Ltd

    Idiopathic Pulmonary Fibrosis (IPF)

    phase 2 small molecule active

    1 trial

  30. AP101-02

    Lacuna Pharma Pty Ltd

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  31. AP31969-M201

    Lacuna Pharma Pty Ltd

    Atrial fibrillation

    phase 2 small molecule active

    1 trial

  32. AP707, Placebo

    Lacuna Pharma Pty Ltd

    Borderline personality disorder

    phase 2 small molecule active

    1 trial

  33. APG-2575CU101

    Lacuna Pharma Pty Ltd

    Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).

    phase 2 small molecule active

    1 trial

  34. API-EAB-2024-01

    Lacuna Pharma Pty Ltd

    Allergies

    phase 2 small molecule active

    1 trial

  35. API-EAD-2024-01

    Lacuna Pharma Pty Ltd

    Allergies

    phase 2 small molecule active

    1 trial

  36. API-EAO-2025-01

    Lacuna Pharma Pty Ltd

    Allergies

    phase 2 small molecule active

    1 trial

  37. APISLIT-DD-G-2025-01

    Lacuna Pharma Pty Ltd

    Allergic rhinitis/rhinoconjunctivitis caused by grass polen allergy

    phase 2 small molecule active

    1 trial

  38. APL2-PNH-209

    Lacuna Pharma Pty Ltd

    Paroxysmal Nocturnal Hemoglobinuria

    phase 2 small molecule active

    1 trial

  39. ART0380C001

    Lacuna Pharma Pty Ltd

    Advanced or Metastatic Solid Tumours

    phase 2 small molecule active

    1 trial

  40. ART6043C001

    Lacuna Pharma Pty Ltd

    Metastatic solid tumors, Advanced solid tumors

    phase 2 small molecule active

    1 trial

  41. ASLAN004-004

    Lacuna Pharma Pty Ltd

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  42. ASND0029

    Lacuna Pharma Pty Ltd

    Locally advanced or metastatic solid tumor malignancies, platinum resistant ovarian cancer, post-anti-pd-1 melanoma, second line or later cervical cancer, neoadjuvant melanoma and neoadjuvant non-small cell lung cancer, post-anti-pd-L1 non-small cell lung cancer, post-anti-pd-L1 small cell lung cancer, second line or later HER2+ breast cancer

    phase 2 small molecule active

    1 trial

  43. ASND0030

    Lacuna Pharma Pty Ltd

    Achondroplasia in Children and Adolescents

    phase 2 small molecule active

    1 trial

  44. ASND0038

    Lacuna Pharma Pty Ltd

    Stage III-IVA Resectable Locoregionall Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)

    phase 2 small molecule active

    1 trial

  45. ASND0042

    Lacuna Pharma Pty Ltd

    Children with Achondroplasia

    phase 2 small molecule active

    1 trial

  46. ASND0045

    Lacuna Pharma Pty Ltd

    Achondroplasia in Children and Adolescents

    phase 2 small molecule active

    1 trial

  47. ASPAVELI 1 080 mg solution for infusion

    Lacuna Pharma Pty Ltd

    complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN)

    phase 2 small molecule active

    1 trial

  48. ATD002

    Lacuna Pharma Pty Ltd

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Anaxis Pharma have?

223 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.